Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine in Surgically Resectable HPV-Negative Head and Neck Cancer
NCT06997094Phase 1Recruiting
- Sponsor
- Mayo Clinic
- Start
- Jan 2026
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of decitabine in head and neck squamous cell carcinoma (HNSCC), sponsored by Mayo Clinic. Primary endpoints: Maximum tolerated dose of preoperative decitabine and Maximum tolerated dose of adjuvant decitabine. Started Jan 2026; status: recruiting.
02
Drugs
decitabine
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06997094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06997094.